Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SIRP alphaV8

SIRP alphaV8

Brief Information

Name:Signal-regulatory protein alpha
Target Synonym:SHPS-1,Macrophage fusion receptor,Brain Ig-like molecule with tyrosine-based activation motifs,MFR,Signal-regulatory protein alpha-1,Signal-regulatory protein alpha-2,CD172a,MyD-1 antigen,Sirp-alpha-3,MYD1,SIRPA,Signal Regulatory Protein Alpha,CD172 Antigen-Like Family Member A,Inhibitory Receptor SHPS-1,PTPNS1,SHPS1,SIRP,P84,Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs,Protein Tyrosine Phosphatase, Non-Receptor Type Substrate 1,Tyrosine-Protein Phosphatase Non-Recept
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

SI8-H82W6-ELISA
 SIRP alphaV8 ELISA

Immobilized Human CD47 Protein, Mouse IgG2a Fc Tag (Cat. No. CD7-H52A5) at 2 μg/mL (100 μL/well) can bind Biotinylated Human SIRP alphaV8 Protein, His,Avitag (Cat. No. SI8-H82W6) with a linear range of 0.02-1.25 μg/mL (QC tested).

SI8-H52H5-MALS-HPLC
Human SIRP alphaV8, His Tag (Cat. No. ) MALS images

The purity of Human SIRP alphaV8, His Tag (Cat. No. SI8-H52H5) is more than 90% and the molecular weight of this protein is around 45-55 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human SIRP alphaV8, His TagHuman SIRP alphaV8, His Tag (Cat. No. SI8-H52H5) ELISA bioactivity

Immobilized Human SIRP alphaV8, His Tag (Cat. No. SI8-H52H5) at 2 μg/mL (100 μL/well) can bind Human CD47, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD7-H52A5) with a linear range of 1-5 ng/mL (QC tested).

Synonym Name

SHPS1,SIRPA,CD172A,BIT,MFR,MYD1,P84,PTPNS1

Background

Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS1) is also known as CD172 antigen-like family member A (CD172a), Macrophage fusion receptor, MyD-1 antigen, Signal-regulatory protein alpha (SIRPA or SIRP alpha) or p84, is a member of the SIRP family, and also belongs to the immunoglobulin superfamily. SIRP alpha is Ubiquitous and highly expressed in brain. SIRPA / CD172a is immunoglobulin-like cell surface receptor for CD47 and acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA / SHPS-1 supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment and may play a key role in intracellular signaling during synaptogenesis and in synaptic function By similarity. SIRPA / MyD1 involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin and mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Relugolix/Estradiol/Norethindrone Acetate E2/NETA Approved Myovant Sciences MYFEMBREE, RYEQO United States Leiomyoma; Menorrhagia Myovant Sciences 2021-05-26 Pain; Endometriosis; Leiomyoma; Uterine Neoplasms; Menorrhagia Details
Elagolix/estradiol/norethindrone acetate Approved Abbvie Inc Oriahnn United States Menorrhagia Abbvie Inc 2020-05-29 Menorrhagia Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BR-105 BR-105; BR105 Phase 1 Clinical BioRay Pharmaceutical Co Ltd, Hisun Biopharmaceutical Co Ltd Neoplasms Details
Q-1801 Q-1801; Q 1801 Phase 1 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours Details
ELA-026 ELA-026 Phase 1 Clinical Electra Therapeutics Inc Lymphohistiocytosis, Hemophagocytic Details
Anzurstobart BMS-986351; CC-95251 Phase 1 Clinical Celgene Corp Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
BYON-4228 BYON-4228 Phase 1 Clinical Byondis Bv Solid tumours; Lymphoma Details
ADU-1805 ADU-1805 Phase 1 Clinical Aduro Biotech Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
BI-765063 OSE-172; BI-765063 Phase 1 Clinical Ose Immunotherapeutics Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
IBC-0966 IBC-0966 Phase 2 Clinical SunHo (China) BioPharmaceutical Co Ltd Neoplasms Details
Recombinant humanized IgG4 anti-SIRPα antibody(Daiichi Sankyo) DS-1103a Phase 1 Clinical Daiichi Sankyo Co Ltd Solid tumours; Breast Neoplasms Details
ES-004 ES-004 Phase 1 Clinical Elpiscience (Shanghai) Biopharma Ltd Solid tumours; Neoplasms Details
BI-765080 Phase 1 Clinical C.H. Boehringer Sohn Ag & Co. Kg Details
LM-101 LM-101 Phase 1 Clinical LaNova Medicines Ltd Leukemia; Solid tumours; Hematologic Neoplasms; Neoplasms Details
TQB-2928 TQB-2928 Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute Details
[89Zr]Zr- BI-765063(Boehringer Ingelheim) Phase 1 Clinical Boehringer Ingelheim Corp Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message